ProMIS Neurosciences Inc. (ON) (PMN) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, ProMIS Neurosciences Inc. (ON) (NASDAQ: PMN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $3.31 (-70.13% 1D, market cap $99.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PMN ranks #529 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PMN carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MIST (Milestone Pharmaceuticals Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $98.3M) and PMVP (PMV Pharmaceuticals Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $101.9M). Among the 5-stock peer group, PMN leads on earnings multiple (N/A) while PMN leads on capital efficiency (-35.0% ROIC).
Per PMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374339), ProMIS Neurosciences Inc. (ON) generated $0 in revenue, -$39.7M in net income, and -$28.1M in free cash flow against $9.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.6 (OVERSOLD (<32))
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While PMN currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.03) and Max Pain ($3.48) forces dealer call-delta covering toward $28.77.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
ProMIS Neurosciences Inc. (ON) (PMN) dropped -70.13% to $3.31, trading at 2% of its 52-week range ($2.84 – $27.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics
The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 293% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raisi
HCA's Q3 results could benefit from higher admissions, occupancy and inpatient revenues, but rising costs and fewer outpatient surgeries cloud the outlook.
Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development (AMEX:SDEV) stock
Universal Health Services' Q3 revenues are expected to rise on higher patient admissions, but surging operating costs and wage pressures could weigh on earnings growth.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PMN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PMN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, ProMIS Neurosciences Inc. (ON) (PMN) ranks #529 by composite RQD confidence (40/100, grade D-) and #662 by equity capitalization ($99.4M). Within this direct 5-issuer industry benchmark cohort, PMN leads on earnings valuation at N/A trailing P/E, while PMN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MIST currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with PMN at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PMN
ACTIVE
ProMIS Neurosciences Inc. (ON) | D- | 40/100 | — | — | -35.0% | -70.13% | $99.4M | Benchmark Subject |
| MIST Milestone Pharmaceuticals Inc. | D | 47/100 | — | — | -35.0% | -7.55% | $98.3M | /mist-vs-pmn → |
| PMVP PMV Pharmaceuticals Inc. | D | 45/100 | — | — | -35.0% | -2.96% | $101.9M | /pmvp-vs-pmn → |
| GNLX Genelux Corporation | E | 29/100 | — | — | -35.0% | -0.95% | $95.0M | /gnlx-vs-pmn → |
| VTVT vTv Therapeutics Inc. (Class A) | E | 33/100 | — | — | -35.0% | -4.59% | $104.3M | /vtvt-vs-pmn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), ProMIS Neurosciences Inc. (ON) (PMN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$39.7M, operating cash flow of -$28.1M, and free cash flow of -$28.1M (-3.4% YoY). On the balance sheet, PMN closed FY2025 with $9.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$39.7M | -$28.1M | -$28.1M | $9.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $2.8M | -$27.2M | -$27.2M | $18.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$13.2M | -$10.8M | -$10.8M | — | — |
As of 2026-11-02, ProMIS Neurosciences Inc. (ON) (NASDAQ: PMN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $3.31 (-70.13% 1D, market cap $99.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PMN ranks #529 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PMN carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MIST (Milestone Pharmaceuticals Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $98.3M) and PMVP (PMV Pharmaceuticals Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $101.9M). Among the 5-stock peer group, PMN leads on earnings multiple (N/A) while PMN leads on capital efficiency (-35.0% ROIC).
Per PMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374339), ProMIS Neurosciences Inc. (ON) generated $0 in revenue, -$39.7M in net income, and -$28.1M in free cash flow against $9.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PMN last traded at $3.31 (-70.13% on volume of 1,639,844 shares), positioning the stock -69.99% below its 50-day simple moving average ($11.03) and -74.28% below its 200-day simple moving average ($12.87). Across its 52-week range of $2.84 to $27.40, PMN sits at the 1.9% percentile with a 14-day RSI of 26.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.90 to $3.72).
Why PMN Stock dropped -70.13% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, PMN scores 40 out of 100, a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
Taken together, the pillar scores indicate that the primary drag is the absence of cash generation and the weak forensic profile. Upside would require a clear improvement in operating economics, which the source data does not show. Valuation tradeoffs are difficult to assess because earnings-based multiples are unavailable.
ProMIS Neurosciences Inc. (ON) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company carries a market capitalization of $0.1B. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M across the periods provided.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-40.2M | $-39.7M | N/A | $-28.1M | $6.1M | N/A |
| FY 2024 | $0.0M | $-16.8M | $2.8M | N/A | $-27.2M | $13.3M | N/A |
| FY 2023 | $0.0M | $-14.3M | $-13.2M | N/A | $-10.8M | N/A | N/A |
Per the SEC financials, operating losses widened from $-14.3M in FY 2023 to $-40.2M in FY 2025, and reported revenue is $0.0M in every period. Gross, operating, and net margins are each recorded as 0% in the market data. The source reports ROIC of -35%, an Altman Z-Score of 2.5, and a Piotroski F-Score of 1/9. Cash declined from $13.3M to $6.1M between FY 2024 and FY 2025, and debt is not reported.
Real-time company headlines, analyst actions, and sector developments for ProMIS Neurosciences Inc. (ON) (PMN) • Click "Debate This Headline" to argue it in the Roar Pit below
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics
The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 293% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raisi
HCA's Q3 results could benefit from higher admissions, occupancy and inpatient revenues, but rising costs and fewer outpatient surgeries cloud the outlook.
Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development (AMEX:SDEV) stock
Universal Health Services' Q3 revenues are expected to rise on higher patient admissions, but surging operating costs and wage pressures could weigh on earnings growth.
Welcome to the PMN (ProMIS Neurosciences Inc. (ON)) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on PMN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless ProMIS Neurosciences Inc. (ON) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on PMN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $11.08 (52-wk range $10.24 - $12.68), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).